Biliary Tract Cancer clinical trials at UC Health
7 in progress, 5 open to new patients

• A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer

  open to eligible people ages 18 years and up

  This study is to define the safety profile and to determine the Maximal tolerated dose regimen and preliminary efficacy of AbGn-107 administered every 28 days (4 weeks) in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal, pancreatic or biliary cancer.

  at UCSF

• My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

  open to eligible people ages 18 years and up

  This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available and/or are not suitable options per the treating physician's judgment.

  at UCSD

• Pembrolizumab and GM-CSF in Biliary Cancer

  open to eligible people ages 18 years and up

  This is an open label phase II trial to examine efficacy and safety of a novel combination of pembrolizumab plus induction GM-CSF in patients with advanced biliary cancers treated at UCSF. This phase II study will examine the efficacy and safety of the novel combination of pembrolizumab plus induction GM-CSF in advanced biliary cancer patients with the hypotheses that the combination may increase proportion of patients with overall response compared to contemporary historical controls, with acceptable safety.

  at UCSF

• Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers

  open to eligible people ages 1 month and up

  This is a Phase 1/2, multi-center, open-label study designed to evaluate the safety and efficacy of LOXO-195 when administered orally to patients age ≥ 1 month and older with NTRK fusion cancers treated with a prior TRK inhibitor.

  at UCLA

• Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)

  open to eligible people ages 12 years and up

  Phase II, multi-center, open-label study of patients with advanced solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3.

  at UCLA

• A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

  Sorry, not currently recruiting here

  The purpose of this open-label nonrandomized Phase 1/2 study is to evaluate INCB001158 in combination with chemotherapy in participants with advanced/metastatic solid tumors.

  at UC Davis

• A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

  Sorry, in progress, not accepting new patients

  The main purpose of this study is to evaluate the efficacy and safety of ramucirumab or merestinib or placebo plus cisplatin and gemcitabine in participants with advanced or metastatic biliary tract cancer.

  at UCSF

Last updated: November 29, 2018